DE68924537D1 - COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO. - Google Patents

COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO.

Info

Publication number
DE68924537D1
DE68924537D1 DE68924537T DE68924537T DE68924537D1 DE 68924537 D1 DE68924537 D1 DE 68924537D1 DE 68924537 T DE68924537 T DE 68924537T DE 68924537 T DE68924537 T DE 68924537T DE 68924537 D1 DE68924537 D1 DE 68924537D1
Authority
DE
Germany
Prior art keywords
tobacco
composition
symptoms caused
treat symptoms
disturbances
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68924537T
Other languages
German (de)
Other versions
DE68924537T2 (en
Inventor
Richard Wurtman
Judith Wurtman
Bonnie Spring
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Application granted granted Critical
Publication of DE68924537D1 publication Critical patent/DE68924537D1/en
Publication of DE68924537T2 publication Critical patent/DE68924537T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions useful in the treatment of disturbances of appetite, disturbances of mood, or both, nicotine withdrawal associated as well as experienced by individuals after discontinuing tobacco use as methods of use therefor. The compositions include serotoninergic drugs, such as d-fenfluramine and fluoxetine.
DE68924537T 1988-10-26 1989-10-25 COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO. Expired - Fee Related DE68924537T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/262,625 US4999382A (en) 1988-10-26 1988-10-26 Compositions for treating tobacco withdrawal symptoms and methods for their use
PCT/US1989/004743 WO1990004387A2 (en) 1988-10-26 1989-10-25 Compositions for treating tobacco withdrawal symptoms

Publications (2)

Publication Number Publication Date
DE68924537D1 true DE68924537D1 (en) 1995-11-16
DE68924537T2 DE68924537T2 (en) 1996-08-01

Family

ID=22998317

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924537T Expired - Fee Related DE68924537T2 (en) 1988-10-26 1989-10-25 COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO.

Country Status (7)

Country Link
US (1) US4999382A (en)
EP (1) EP0440704B1 (en)
JP (1) JP2997280B2 (en)
AT (1) ATE128864T1 (en)
CA (1) CA2001572C (en)
DE (1) DE68924537T2 (en)
WO (1) WO1990004387A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69004529T2 (en) * 1989-08-30 1994-02-24 Pfizer Use of sertraline to treat chemical addiction.
US5455254A (en) * 1991-02-15 1995-10-03 Mondadori; Cesare Substituted benzofuranylpiperidine as a nootropic agent
DK36391D0 (en) * 1991-03-01 1991-03-01 Lundbeck & Co As H APPLICATION OF PIPERIDYL-SUBSTITUTED INDUSTRIAL DERIVATIVES FOR TREATMENT OF SUBSTANCE ABUSE
BE1005200A3 (en) * 1991-08-27 1993-05-25 Vandendael Kathleen Mariette Use of tryptophan and a nutritional formulation containing tryptophan
AU2446895A (en) * 1994-04-22 1995-11-16 Assistance Publique - Hopitaux De Paris Use of mao-a inhibitors for the manufacture of a medicament in the treatment of tobacco withdrawal symptoms in smokers
US6004990A (en) * 1994-06-03 1999-12-21 Zebra Pharmaceuticals Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
WO1995033455A1 (en) 1994-06-03 1995-12-14 Elmaleh David R Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof
BR9501972A (en) * 1995-05-09 1997-08-26 Tostes Luiz Roberto Mallat Pharmaceutical composition method for treating alcohol dependence or abuse and method for treating psychiatric disorders genetically related to alcoholism
WO1996040085A2 (en) 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6203817B1 (en) 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
US5910319A (en) * 1997-05-29 1999-06-08 Eli Lilly And Company Fluoxetine enteric pellets and methods for their preparation and use
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US6617361B2 (en) 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
EP1363634A2 (en) * 2000-08-16 2003-11-26 PHARMACIA &amp; UPJOHN COMPANY Compounds for the treatment of addictive disorders
BR0316054A (en) * 2002-11-08 2005-09-20 Mclean Hospital Corp Tobacco addiction and deprivation treatment compounds
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74222A (en) * 1984-02-06 1988-07-31 Lilly Co Eli 6-substituted-4-dialkylamino tetrahydrobenz(c,d)indoles,their preparation and pharmaceutical compositions comprising them
JP2765845B2 (en) * 1986-11-21 1998-06-18 グラクソ、グループ、リミテッド Remedies for prevention of discontinuation syndrome
DE3822792C2 (en) * 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
DE3736974A1 (en) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg USE OF 2-PYRIMIDINYL-1-PIPERAZINE DERIVATIVES

Also Published As

Publication number Publication date
JPH04501413A (en) 1992-03-12
EP0440704A1 (en) 1991-08-14
CA2001572C (en) 2001-01-02
ATE128864T1 (en) 1995-10-15
EP0440704B1 (en) 1995-10-11
US4999382A (en) 1991-03-12
DE68924537T2 (en) 1996-08-01
JP2997280B2 (en) 2000-01-11
WO1990004387A3 (en) 1990-06-28
CA2001572A1 (en) 1990-04-26
WO1990004387A2 (en) 1990-05-03

Similar Documents

Publication Publication Date Title
DE68924537D1 (en) COMPOSITION TO TREAT SYMPTOMS CAUSED BY TOBACCO.
DE69027865D1 (en) COMPOSITIONS containing omega conotoxin peptide derivatives and their use for the treatment of ischemic-like neuronal damage
ATE257386T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING A MIXTURE OF SELF-CROSS-LINKED AND NON-SELF-CROSS-LINKED HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
ATE119040T1 (en) CENTRAL CHOLECYSTOKIN ANTAGONISTS FOR THE TREATMENT OF PSYCHIATRIC DISEASES.
BR9106537A (en) SMOKING COMPOSITION AND PROCESS FOR ADDING NICOTINE TO A SMOKING MATERIAL
DE10199020I1 (en) Galanthamine or its analogues for the treatment of Alzheimer&#39;s disease
ATE211129T1 (en) INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION
DE3684190D1 (en) USE OF TETRAHYDROBIOPTERINES FOR PRODUCING A MEDICINE FOR TREATING CHILDREN&#39;S AUTISM.
DE3851203D1 (en) Use of GHL-Cu derivatives in the manufacture of a medicament to stimulate hair growth.
DE69132688D1 (en) METHOD FOR TREATING AND PREVENTING TYPE-1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
PT977564E (en) FORCOLINA FOR THE PROMOTION OF BODY MASS MAGRA
ATE237633T1 (en) ANALOGUE OF KERATINOCYTE GROWTH FACTOR
DE3856295D1 (en) TREATMENT OF PREMIUM OR LATE LUTEAL PHASE SYNDROME
DE69027220D1 (en) COMPOSITION AND METHOD FOR TREATING PAINFUL INFLAMMABLE OR ALLERGIC DISEASES
Haggard et al. The effects of cigarette smoking upon the blood sugar
IL58103A0 (en) Sila-substituted 1,4-dihydropyridine derivatives their production and pharmaceutical compositions containing them
ATE89728T1 (en) USE OF DIHYDROERGOTAMINE AND ITS SALTS FOR THE LOCAL TREATMENT OF TROPHIC DISORDERS.
DE3789562D1 (en) Process for the treatment of metal carbide composites in relation to their structure and composition.
DE3676640D1 (en) PRAZOSINE-PIRBUTEROL MIXTURE FOR BRONCH DILATATION.
ATE157010T1 (en) A COMPOSITION CONTAINING AMYLIN OR AMYLIN ANALOGUE, WHICH ALSO OPTIONALLY CONTAINS INSULIN, FOR THE TREATMENT OF ANOREXIA AND RELATED CONDITIONS
FR2539625B1 (en) ALCOHOLIC OR HYDROALCOHOLIC COMPOSITIONS CONTAINING NATURAL ESSENCES AND BENZYLIDENE CAMPHOR DERIVATIVES
ATE244008T1 (en) USE OF MACROLIDS TO TREAT ACUTE LUNG INJURY
DK0406216T3 (en) Protein-S-containing pharmaceutical composition
ES488301A0 (en) PROCEDURE FOR OBTAINING DEHYDROPEPTIDES
DE69023006D1 (en) METHOD FOR TREATING THROMBOCYTOPENIA AND PHARMACEUTICAL COMPOSITIONS SUITABLE FOR THIS.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee